ISOLAGEN INC - 10-Q Quarterly Report

Back to GetFilings.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10 - Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2003

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

ISOLAGEN, INC.
(Exact name of registrant as specified in its charter)

Delaware 0-12666 87-0458888
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)

2500 Wilcrest, 5th Floor
Houston, Texas 77042
(Address of principal executive offices, including zip code)

(713) 780-4754
(Registrant's telephone number, including area code)

Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for any shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Check whether the registrant is an accelerated filer (as defined in Rule 12b-2
of the Exchange Act.) [ ] Yes [X] No

As of August 7, 2003, issuer had 15,916,769 shares of issued and outstanding
common stock, par value $0.001.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Isolagen, Inc.
(A Development Stage Company)
Consolidated Balance Sheets

The accompanying notes are an integral part of these statements.

1

Isolagen, Inc.
(A Development Stage Company)
Consolidated Statements of Operations
(unaudited)

The accompanying notes are an integral part of these statements.

2

Isolagen, Inc.
(A Development Stage Company)
Consolidated Statements of Operations
(unaudited)

The accompanying notes are an integral part of these statements.

3

Isolagen, Inc.
(A Development Stage Company)
Consolidated Statements of Cash Flows

The accompanying notes are an integral part of these statements.

4

Isolagen, Inc.
(A Development Stage Company)
Notes to Unaudited Consolidated Financial Statements

NOTE 1- BASIS OF PRESENTATION, BUSINESS AND ORGANIZATION

Isolagen, Inc. f/k/a American Financial Holding, Inc., a Delaware
corporation ("Isolagen" or the "Company") is the parent company of Isolagen
Technologies, Inc., a Delaware corporation and wholly-owned subsidiary of the
Company ("Isolagen Technologies"). Isolagen Technologies is the parent company
of Isolagen Europe Limited ("Isolagen Europe"), a company organized under the
laws of the United Kingdom and wholly-owned subsidiary of Isolagen Technologies.
Isolagen Technologies is the parent company of Isolagen Australia Pty Limited
("Isolagen Australia"), a company organized under the laws of the Australia and
wholly-owned subsidiary of Isolagen Technologies. The common stock, par value
$0.001 per share, of the Company ("Common Stock") is traded on the American
Stock Exchange ("AMEX") under the symbol "ILE."

Isolagen is an emerging pharmaceutical bioscience company specializing
in the development and commercialization of autologous cellular therapy for hard
and soft tissue regeneration and other therapies. Isolagen currently holds five
patents. Autologous cellular therapy is a process whereby a patient's own cells
are extracted, reproduced and then reintroduced to the patient for specific
cosmetic and medical applications. Unlike other applications for the treatment
of dermal defects, Isolagen utilizes only the patient's unique, living cells to
produce the patient's own collagen. There is no foreign substance utilized in
this treatment protocol. Isolagen's goal is to become an industry leader in the
research, development and commercialization of autologous cellular therapy which
stimulate a patient's own collagen production.

In 1995, Isolagen Technologies began treating a small percentage of
patients to correct defects (e.g., wrinkles, depressions and scarring) in the
patient's face. Between 1995 and 1999, approximately 200 doctors utilized the
Isolagen Process on approximately 963 patients with positive results. In 1997,
the FDA began regulating the science of biologics. Biologics, in contrast to
drugs that are chemically synthesized, are derived from living sources (such as
humans, animals, and microorganisms) like the Isolagen Process. In 1995, when
Isolagen Technologies began operations, the FDA had no regulations governing
this area of biologics. After reviewing the new regulations and seeking the
advice of consultants, Isolagen concluded that the use of the Isolagen Process
in cosmetic applications did not require the approval of the FDA. In 1999,
Isolagen Technologies filed a request for authorization from the FDA to
administer an investigational drug or biological product to humans. Such
authorization must be secured prior to commercialization of any new drug or
biological product. The FDA placed the authorization on clinical hold until
Isolagen Technologies' manufacturing processes and procedures were changed to
meet these new biologics standards, and FDA approval is obtained. In April 2002,
the FDA approved Isolagen's Investigational New Drug Application ("IND") for the
treatment of wrinkles and scars and clinical trial are underway. The Company's
Phase III trial for dermal defects has commenced, is being conducted in ten
sites, and involves physicians who are either plastic surgeons or dermatologists
with practices that emphasize aesthetic procedures. The patients' enrollment has
been completed and totals one hundred fifty-two patients. To date, over 90% of
the patients have had their first consultation. The first patients are scheduled
to begin their injections in August 2003 with the final patient injection
scheduled for the end of September 2003. This Phase III trial is a double-blind
study with 75% of the patients receiving the therapeutic dosage and the
remaining 25% receiving a placebo. In addition, in January of 2003, Isolagen
commenced a double-blind Phase II trial under the IND, which is a two-site dose
ranging study of forty patients. Isolagen expects to complete its analysis of
the data from the Phase II trial during the fourth quarter of 2003. Finally,
Isolagen also has a Phase I clinical trial of twenty-one patients in progress
for dental applications addressing gingival recession. Isolagen expects to
complete this study in the first quarter of 2004.

The Company's goal is to become an industry leader in the research,
development and commercialization of autologous cellular therapy which stimulate
a patient's own collagen production. The Company, through Isolagen Europe, has
commenced commercial operations in the United Kingdom and is pursuing commercial
operations through subsidiaries, joint ventures or license arrangements in
Australia, South Korea, Hong Kong, Brazil, Mexico and elsewhere. The Company is
investigating regulatory and other requirements in these countries and
evaluating markets and potential joint venture partners and licensees. In July
2003, the Company received License No. 174347 from the Therapeutic Goods
Administration ("TGA"), in Australia, to begin the manufacture of autologous
fibroblasts including the initiation of primary cultures of fibroblasts, the
propagation of fibroblasts, the

5

harvesting of cultured fibroblasts, the storage of cultured fibroblasts and
release for supply of cultured fibroblasts. The Company is not in a position to
predict, when or if licenses will be granted in any jurisdiction.

Through June 30, 2003, the Company has been primarily engaged in
developing its initial product technology, recruiting personnel, commencing its
United Kingdom operations and raising capital. In the course of its development
activities, the Company has sustained losses and expects such losses to continue
through 2004. The Company will finance its operations primarily through its
existing cash, future financing and revenues.

The Company's ability to operate profitably under its current business
plan is largely contingent upon its success in obtaining further sources of debt
and equity capital, prompt regulatory approval to sell its products and upon its
continued expansion. The Company will require additional capital in the future
to expand its operations. No assurance can be given that the Company will be
able to obtain any such additional capital, either through equity or debt
financing, on satisfactory terms or at all. Additionally, no assurance can be
given that any such financing, if obtained, will be adequate to meet the
Company's ultimate capital needs and to support the Company's growth. If
adequate capital cannot be obtained on satisfactory terms, the Company's
operations could be negatively impacted.

If the Company achieves growth in its operations in the next few years,
such growth could place a strain on its management, administrative, operational
and financial infrastructure. The Company's ability to manage its operations and
growth requires the continued improvement of operational, financial and
management controls, reporting systems and procedures. In addition, the Company
may find it necessary to hire additional management, financial and sales and
marketing personnel to manage the Company's expanding operations. If the Company
is unable to manage this growth effectively and successfully, the Company's
business, operating results and financial condition may be materially adversely
affected.

As of June 30, 2003, the Company had a cash balance of $3,292,242. As
of August 7, 2003, the Company had a cash balance of approximately $2.2 million.
The long-term viability of the Company is dependent upon successful operation of
its business and the ability to raise additional debt and equity within the near
future.

Acquisition and Merger

On August 10, 2001, Isolagen Technologies consummated a merger with
American Financial Holdings, Inc. ("AFH") and Gemini IX, Inc. ("Gemini").
Pursuant to an Agreement and Plan of Merger, dated August 1, 2001, by and among
the Company, ISO Acquisition Corp, a Delaware corporation and wholly-owned
subsidiary of the Company ("Merger Sub"), Isolagen Technologies, a Delaware
corporation, Gemini, a Delaware corporation, and William J Boss, Jr., Olga Marko
and Dennis McGill, stockholders of Isolagen (the "Merger Agreement"), the
Company acquired in a privately negotiated transaction 100% of the issued and
outstanding capital stock of Isolagen Technologies. Pursuant to the terms of the
Merger Agreement, Merger Sub, together with Gemini, merged with and into
Isolagen Technologies (the "Merger"), and Isolagen Technologies was the
surviving corporation of the Merger. AFH was a non-operating, public shell
company with limited assets. Consequently, the substance of the merger
transaction was a capital transaction rather than a business combination. The
transaction was equivalent to the issuance of stock by AFH for the net assets of
the Isolagen Technologies and Gemini, accompanied by a recapitalization and
private placement of common stock of AFH. The accounting is identical to that
resulting from a reverse acquisition, except that no goodwill or other
intangibles are recorded. AFH issued an aggregate of 9,756,372 shares of
restricted common stock, par value $0.001 per share, as consideration for the
Merger, to retire certain debts of Isolagen Technologies and in connection with
certain bridge loans of Isolagen Technologies.

Prior to the Merger, Isolagen had no active business and was seeking
funding to begin U.S. Food and Drug Administration ("FDA") trials of the
Isolagen Process.

Simultaneous with the Merger, AFH sold 1,346,669 shares of restricted
common stock to certain accredited investors in a private placement transaction.
The consideration paid by such investors for the shares of Common Stock
aggregated $2,020,000 in transactions exempt from the registration requirements
of the Securities Act. The net cash proceeds of this private placement were used
to fund Isolagen Technologies' research and development projects and the initial
FDA trials of the Isolagen Process, to explore the viability of entering foreign
markets, to provide working capital and for general corporate purposes.
Additionally, $1,450,000 principal of Isolagen Technologies' debt and

6

approximately $625,000 of accrued liabilities were converted to equity. On
November 13, 2001, AFH changed its name to Isolagen, Inc.

Basis of Presentation

The financial statements presented include the consolidated balance
sheet of Isolagen, Inc. and its wholly-owned subsidiaries, Isolagen
Technologies, Inc., Isolagen Europe Limited and Isolagen Australia Pty Limited,
at June 30, 2003 and December 31, 2002. The consolidated statements of
operations and cash flows for six and three month periods ended June 30, 2003
and June 30, 2002 include Isolagen, Inc. and its wholly-owned subsidiaries. All
significant intercompany transactions have been eliminated.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Information

The financial statements included herein, which have not been audited
pursuant to the rules and regulations of the Securities and Exchange Commission,
reflect all adjustments which, in the opinion of management, are necessary for a
fair presentation of financial position, results of operations and cash flows
for the interim periods on a basis consistent with the annual audited
statements. All such adjustments are of a normal recurring nature. The results
of operations for interim periods are not necessarily indicative of the results
that may be expected for any other interim period of a full year. Certain
information, accounting policies and footnote disclosures normally included in
financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been omitted pursuant to such
rules and regulation, although the Company believes that the disclosures are
adequate to make the information presented not misleading. These financial
statements should be read in conjunction with the Company's audited financial
statements included in the Company's current report on Form 10-KSB filed with
the Securities and Exchange Commission on March 31, 2003.

Statement of cash flows

For purposes of the statements of cash flows, the Company considers all
highly liquid debt instruments purchased with an original maturity of three
months or less to be cash equivalents.

Concentration of credit risk

The Company maintains its cash with a major U.S. domestic bank. The
amounts held in this bank exceed the insured limit of $100,000 from time to
time. The terms of these deposits are on demand to minimize risk. The Company
has not incurred losses related to these deposits.

The Company is subject to risks common to companies in the development
stage including, but not limited to, development of new products, development of
markets and distribution channels, dependence on key personnel, and the ability
to obtain additional capital as needed to fund its product plans. The Company
has a limited operating history and has yet to generate any significant revenues
from customers. To date, the Company has been funded by private debt and equity
financings. The Company's ultimate success is dependent upon its ability to
raise additional capital and to successfully develop and market its products.

The products developed by the Company require approvals from the United
States FDA or other international regulatory agencies prior to commercial sales.
There can be no assurance that all of the Company's products will receive the
necessary approvals. If the Company was denied such approvals or such approvals
were delayed, it may have a material adverse impact on the Company.

Inventory

Inventory primarily consists of raw materials used in the Isolagen
Process. Inventory is stated at the lower of cost or market and cost is
determined by the weighted average method.

7

Property and equipment

Property and equipment, consisting primarily of lab equipment, computer
equipment, leasehold improvements, and office furniture and fixtures is carried
at cost less accumulated depreciation. Depreciation for financial reporting
purposes is provided by the straight-line method over the estimated useful lives
of three to five years subject to half year convention. Leasehold improvements
are amortized using the straight-line method over the remaining life of the
lease. The cost of repairs and maintenance is charged against income as
incurred.

Intangible Assets

In the first quarter of 2003, the Company entered into an Intellectual
Property Purchase Agreement to acquire two pending patent applications. As
consideration, the Company issued the seller 100,000 shares of its Common Stock
and royalty equal to (a) 5% of all revenues recognized by the Company or its
Affiliates from commercial application of the Intellectual Property made,
provided, distributed, sold or manufactured directly by the Company or its
Affiliates, or (b) 25% of all revenues recognized by the Company or its
Affiliates from licensing, sublicensing, transferring or selling the
Intellectual Property to a third party, without offset or deduction for general
and administrative or operating costs, subject to a total maximum royalty of $2
million. The pending patent applications are recorded as intangible assets at
their acquisition cost and will be amortized over their estimated useful lives
on a straight-line basis.

Earnings per share data

Basic earnings (loss) per share is calculated based on the weighted
average common shares outstanding during the period. Diluted earnings per share
also gives effect to the dilutive effect of stock options, warrants and
convertible preferred stock (calculated based on the treasury stock method). The
Company does not present diluted earnings per share for years in which it
incurred net losses as the effect is antidilutive.

Shares of Isolagen common stock outstanding prior to the Merger were
deemed converted to its equivalent shares of the Company's common stock using a
conversion factor as defined in the Merger Agreement.

Stock-based compensation

The Company accounts for its stock-based compensation under the
provisions of Statement of Financial Accounting Standards ("SFAS") No. 123 -
"Accounting for Stock Based Compensation." Under SFAS No. 123, the Company is
permitted to either record expenses for stock options and other employee
compensation plans based on their fair value at the date of grant or to continue
to apply its current accounting policy under Accounting Principles Board Opinion
No. 25 "Accounting for Stock Issued to Employees," ("APB No. 25"), and recognize
compensation expense, if any, based on the intrinsic value of the equity
instrument at the measurement date. The Company elected to continue following
the provisions of APB No. 25.

In December 2002, the Financial Accounting Standards Board ("FASB")
issued SFAS No. 148, "Accounting for Stock-Based Compensation-Transition and
Disclosure". This statement provides guidance for those companies wishing to
voluntarily change to the fair value based method of accounting for stock-based
compensation. The statement also amends the disclosure requirements of SFAS No,
123, requiring prominent disclosure in annual and interim financial statements
regarding a company's method for accounting for stock-based employee
compensation and the effect of the method on reported results. While Isolagen
continues to utilize the disclosure-only provisions of SFAS No. 123, it has
modified its disclosures to comply with the new statement.

Income taxes

An asset and liability approach is used for financial accounting and
reporting for income taxes. Deferred income taxes arise from temporary
differences between income tax and financial reporting and principally relate to
recognition of revenue and expenses in different periods for financial and tax
accounting purposes and are measured using currently enacted tax rates and laws.
In addition, a deferred tax asset can be generated by net operating loss
carryforwards ("NOLs"). If it is more likely than not that some portion or all
of a deferred tax asset will not be realized, a valuation allowance is
recognized.

8

Revenue recognition

The Company recognizes revenue from product sales when goods are
shipped and the risk of loss transfers to the customer. Revenue from licenses
and other upfront fees are recognized on a ratable basis over the term of the
respective agreement. Milestone payments are recognized upon successful
completion of a performance milestone event. Any amounts received in advance of
performance are recorded as deferred revenue. The Company recognizes revenue
over the period the service is performed in accordance with SEC Staff Accounting
Bulletin No. 101, "Revenue Recognition in Financial Statements" ("SAB 101"). SAB
101 requires that four basic criteria must be met before revenue can be
recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has
occurred or services rendered, (3) the fee is fixed and determinable, and (4)
collectibility is reasonably assured. The Company believes, relative to sales of
the Isolagen Process, that all of these conditions are met at the time of
shipment.

Foreign Currency Translation

The financial position and results of operations of the Company's
foreign subsidiaries are generally determined using the local currency as the
functional currency. Assets and liabilities of these subsidiaries are translated
at the exchange rate in effect at each year-end. Income statement accounts are
translated at the average rate of exchange prevailing during the year.
Adjustments arising from the use of differing exchange rates from period to
period are included in other comprehensive income in stockholders' equity. Gains
and losses resulting from foreign currency transactions are included in earnings
and have not been material in any one year.

Comprehensive Income

Comprehensive income encompasses all changes in equity other than those
with stockholders and consists of net earnings and foreign currency translation
adjustments. The Company does not provide for U.S. income taxes on foreign
currency translation adjustments since it does not provide for such taxes on
undistributed earnings of foreign subsidiaries.

Research and development expenses

Research and development expenses include direct costs,
research-related overhead, and costs associated with improved process science,
manufacturing and cost reduction are charged to operations as incurred.

Estimates

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.

Recent accounting pronouncements

In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation-Transition and Disclosure". This statement provides
guidance for those companies wishing to voluntarily change to the fair value
based method of accounting for stock-based compensation. The statement also
amends the disclosure requirements of Statement 123, requiring prominent
disclosure in annual and interim financial statements regarding a company's
method for accounting for stock-based employee compensation and the effect of
the method on reported results. While Isolagen continues to utilize the
disclosure-only provisions of SFAS No. 123, it has modified its disclosures to
comply with the new statement.

In January 2003, the FASB issued FIN 46, "Consolidation of Variable
Interest Entities", which requires the consolidation of variable interest
entities. FIN 46 is applicable to variable interest entities created after
January 31, 2003. Variable interest entities created prior to February 1, 2003
must be consolidated effective July 1, 2003. Isolagen adopted FIN 46 in the
quarter ended June 30, 2003, and it did not have a material impact on our
financial position or results of operations.

9

In April 2003, the FASB issued SFAS No. 149, Amendment of Statement 133
on Derivative Instruments and Hedging Activities", which amends and clarifies
financial accounting and reporting for derivative instruments, including certain
derivative instruments embedded in other contracts, and for hedging activities
under SFAS 133. SFAS 149 is effective for contracts entered into or modified
after June 30, 2003, and for hedging relationships designated after June 30,
2003. Isolagen will adopt SFAS 149 effective July 1, 2003, and does not expect
that the provisions of SFAS 149 will have a material impact on the Company's
financial position or results of operations.

In May 2003, the FASB issued SFAS No. 150, Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity". SFAS
150 requires that certain financial instruments, which under previous guidance
were accounted for as equity, must now be accounted for as liabilities. The
financial instruments affected include mandatory redeemable stock, certain
financial instruments that require or may require the issuer to buy back some of
its shares in exchange for cash or other assets and certain obligations that can
be settled with shares of stock. SFAS 150 is effective for all financial
instruments entered into or modified after May 31, 2003, and otherwise is
effective at the beginning of the first interim period beginning after June 15,
2003. SFAS 150 was adopted in the quarter ended June 30, 2003 and it did not
have an impact of the Company's financial positions or results of operations.

NOTE 3- CONTINGENCIES

On October 9, 1996, the Company was advised by the Enforcement Division
of the Securities and Exchange Commission (the "Commission") that it is
considering recommending that the Commission bring an enforcement action, which
could include a civil penalty, against the Company in U.S. District Court for
failing to file timely periodic reports in violation of Section 13(a) of the
Securities and Exchange Act of 1934 and the rules thereunder.

In October 1996, the Company also received a request for the voluntary
production of information to the Enforcement Division of the Commission related
to the resignation of Coopers & Lybrand LLP and the termination of Arthur
Andersen LLP and the appointment of Jones, Jensen & Company as the Company's
independent public accountants and the reasons therefore. In addition, the
Company was requested to provide certain information respecting its previous
sales of securities. The Company cooperated in providing information in response
to these inquiries in early 1997. The Company has not been advised of the
outcome of the foregoing, and has had no further contact by the Enforcement
Division of the Commission.

NOTE 4 - EQUITY

During the six months ended June 30, 2003, the Company issued 61,600
shares of common stock for cash totaling $92,400 in connection with the exercise
of stock options and issued 114,598 shares of common stock in exchange for
cashless exercise of warrants.

In May 2003, the Company sold in a private offering 155,750 shares of
Series B Convertible Preferred Stock, par value $0.001 per share, at an offering
price of $28 per share. Each share of Series B preferred stock is convertible
into 8 shares of common stock at any time after issuance and accrues dividends
at 6% per annum payable in cash or additional shares of Series B Preferred
Stock. After deducting the costs and expenses associated with the sale, the
Company received cash totaling $3,919,078. In conjunction with the private
offering, the Company issued to the placement agent warrants to purchase 124,600
shares of common stock with an exercise price of $3.50 per share. The warrants
are exercisable immediately after grant and expire five years thereafter.

In April 2003, the Company issued 150,000 warrants to purchase its
common stock with an exercise price of $3.50 per share in conjunction with a
distribution agreement. The warrants vest over a three year period, subject to
certain acceleration clauses. The Company recognized consulting expenses
totaling $22,391 during the three months ended June 30, 2002 based on the fair
value of the warrants granted on the grant date.

In May 2003, the Company issued 150,000 options to purchase its common
stock with an exercise price of $3.50 per share under the 2001 Stock Option Plan
("Stock Option Plan"). The options vest over a three year period from the date
of grant. The Company recognized compensation expense totaling $8,750 during the
three months ended June 30, 2002 based on the options intrinsic value on the
grant date. Had compensation costs for all options issued

10

under the Stock Option Plan been determined based on the fair value at the grant
date consistent with the provisions of SFAS No. 123, net income and net income
per share would have decreased to the pro forma amounts indicated below:

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.

FORWARD-LOOKING INFORMATION

This report contains certain "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of
the Securities Exchange Act of 1934, as amended, and information relating to
Isolagen that is based on management's exercise of business judgment as well as
assumptions made by and information currently available to management. When used
in this document and other documents, releases and reports released by us, the
words "anticipate," "believe," "estimate," "expect," and "intend" and words of
similar import, are intended to identify any forward-looking statements. You
should not place undue reliance on these forward-looking statements. These
statements reflect our current view of future events and are subject to certain
risks and uncertainties as noted below. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, our
actual results could differ materially from those anticipated in these
forward-looking statements. Actual events, transactions and results may
materially differ from the anticipated events, transactions or results described
in such statements. The discovery and development of applications for autologous
cellular therapy are subject to substantial risks and uncertainties. There can
be no assurance that Isolagen's trials relating to autologous cellular therapy
applications for the treatment of dermal defects or gingival recession can be
conducted within the timeframe that Isolagen expects, that such trials will
yield positive results, or that additional applications for the
commercialization of autologous cellular therapy can be identified and advanced
into human clinical trials. These and other factors, some of which are described
below, could cause future results to differ materially from the expectations
expressed in this report. Although we believe that our expectations are based on
reasonable assumptions, we can give no assurance that our expectations will
materialize. Many factors could cause actual results to differ materially from
our forward looking statements. Several of these factors include, without
limitation:

o our ability to develop autologous cellular therapies that have
specific applications in cosmetic dermatology, and our ability to
explore (and possibly develop) applications for periodontal
disease, reconstructive dentistry and other health-related
markets;

o whether our clinical human trials relating to autologous cellular
therapy applications for the treatment of dermal defects or
gingival recession can be conducted within the timeframe that we
expect, whether such trials will yield positive results, or
whether additional applications for the commercialization of
autologous cellular therapy can be identified by us and advanced
into human clinical trials;

o our ability to provide and deliver any autologous cellular
therapies that we may develop, on a basis is that is cost
competitive with other therapies, drugs and treatments that may be
provided by our competitors;

o our ability to finance our business;

11

o our ability to maintain our current pricing model;

o our ability to decrease our cost of goods sold;

o a stable interest rate market in the world, and specifically the
countries we are doing business in or plan to do business in;

o management's best estimate on the patient data including patients
started and patients completed;

o a stable currency rate environment in the world, and specifically
the countries we are doing business in or plan to do business in;

o our ability to receive requisite regulatory approvals in the
United States, European Community, Australia, South Korea, Hong
Kong, Mexico, and our ability to retain the licenses that we have
obtained and may obtain; and the absence of adverse regulatory
developments in the United States, European Community, Australia,
South Korea, Hong Kong, Mexico or any other country we plan to do
business in;

o continued availability of supplies at the current prices;

o no new entrance of competitive products in our markets;

o no adverse publicity related to our products or the Company
itself;

o no adverse claims relating to our Intellectual Property;

o the adoption of new, or changes in, accounting principles; legal
proceedings;

o our ability to maintain compliance with the American Stock
Exchange requirements for continued listing of our common stock;

o the costs inherent with complying with new statutes and
regulations applicable to public reporting companies, such as the
Sarbanes-Oxley Act of 2002;

o our ability to efficiently integrate future acquisitions, if any;

o other new lines of business that the Company may enter in the
future; and

o other risks referenced from time to time elsewhere in this report
and in our filings with the SEC.

We undertake no obligation and do not intend to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect the
occurrence of any unanticipated events.

GENERAL

Isolagen is a Houston, Texas based emerging pharmaceutical bioscience
company which has focused its efforts in the development and commercialization
of autologous cellular technology that has specific applications in cosmetic
dermatology and is exploring applications for periodontal disease,
reconstructive dentistry and other health-related markets. Autologous cellular
therapy is a process whereby a patient's own cells are extracted, reproduced and
then reintroduced to the patient for specific cosmetic and medical applications.
Unlike other applications for the treatment of dermal defects, Isolagen utilizes
only the patient's unique, living cells to produce the patient's own collagen.
There is no foreign substance utilized in this treatment protocol. Isolagen's
goal is to become the industry leader in the research, development and
commercialization of autologous cellular therapy which stimulate a patient's own
collagen production.

CRITICAL ACCOUNTING POLICIES

The following discussion and analysis of financial condition and
results of operations are based upon the Company's consolidated financial
statements, which have been prepared in conformity with accounting principles
generally accepted in the United States. The preparation of these financial
statements requires management to make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues, expenses and related
disclosures. On an on-going basis, the Company evaluates its estimates and
assumptions, including but not limited to those related to the impairment of
long-lived assets, reserves for doubtful accounts, revenue recognition and
certain accrued liabilities. The Company bases its estimates on historical
experience and various other assumptions that are believed to be reasonable
under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.

12

Revenue Recognition: The Company recognizes revenue from product sales
when goods are shipped and the risk of loss transfers to the customer. Revenue
from licenses and other upfront fees are recognized on a ratable basis over the
term of the respective agreement. Milestone payments are recognized upon
successful completion of a performance milestone event. Any amounts received in
advance of performance are recorded as deferred revenue. The Company recognizes
revenue over the period the service is performed in accordance with SEC Staff
Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" ("SAB
101"). SAB 101 requires that four basic criteria must be met before revenue can
be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery
has occurred or services rendered, (3) the fee is fixed and determinable, and
(4) collectibility is reasonably assured. The Company believes, relative to
sales of the Isolagen Process, that all of these conditions are met at the time
of shipment.

Research and development expenses: Research and development expenses
include direct costs, research-related overhead, and costs associated with
improved process science, manufacturing and cost reduction are charged to
operations as incurred.

Stock-based compensation: The Company accounts for its stock-based
compensation under the provisions of SFAS No. 123 - "Accounting for Stock Based
Compensation." Under SFAS No. 123, the Company is permitted to either record
expenses for stock options and other employee compensation plans based on their
fair value at the date of grant or to continue to apply its current accounting
policy under Accounting Principles Board Opinion No. 25 "Accounting for Stock
Issued to Employees," ("APB NO. 25"), and recognize compensation expense, if
any, based on the intrinsic value of the equity instrument at the measurement
date. The Company elected to continue following the provisions of APB No. 25.

In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation-Transition and Disclosure." This statement provides
guidance for those companies wishing to voluntarily change to the fair value
based method of accounting for stock-based compensation. The statement also
amends the disclosure requirements of SFAS No. 123, requiring prominent
disclosure in annual and interim financial statements regarding a company's
method for accounting for stock-based employee compensation and the effect of
the method on reported results. While Isolagen continues to utilize the
disclosure-only provisions of SFAS No. 123, it has modified its disclosures to
comply with the new statement.

RESULTS OF OPERATIONS

Comparison of the six months ending June 30, 2003 and 2002

REVENUES. Revenues increased $37,278, to $79,796 for the six months
ended June 30, 2003 compared to $42,518 for the six months ended June 30, 2002.
The increase in revenues is primarily attributable to the commencement of
operations in the United Kingdom. Included in the six months ended June 30, 2002
was $40,000 in license fees recognized which did not recur in the six months
ended June 30, 2003.

The Isolagen Process involves a patient's doctor obtaining an
approximately 3 mm punch skin sample from the patient. The skin sample is packed
in a container provided by the Company and shipped overnight to the Company's
laboratory. The specimen is then cultured utilizing the Company's patented
Isolagen Process. This process separates the cell, called a fibroblast, from the
rest of the tissue then multiplies these fibroblasts. Approximately six (6)
weeks later, approximately 1 ml of the patient's cells is also sent to the
doctor for treatment. Additional amounts of approximately 1 ml are available for
re-injection every two (2) to three (3) weeks. The Company recognizes one-third
of the revenue associated with each treatment upon the shipment of the first
injection to the patient's doctor, an additional one-third of revenue associated
with each treatment is recognized upon shipment of the second injection to the
patient's doctor, and the remaining one-third is recognized upon the shipment of
the last injection to the patient's doctor.

In addition, those revenues which the Company did recognize during the
first six months of 2003 from its United Kingdom operations were in part reduced
by promotional incentives provided by the Company to doctors utilizing the
Isolagen Process. The Company expects to continue providing such promotional
incentives to doctor's during the introduction phase of the Isolagen Process in
the United Kingdom.

13

COST OF SALES. Costs of sales increased to $48,861 for the six months
ended June 30, 2003 compared to $0 for the six months ended June 30, 2002. The
increase in cost of sales is primarily related to the commencement of operations
in the United Kingdom.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and
administrative expenses increased 136%, or $2,606,131, to $4,527,594 for the six
months ended June 30, 2003 compared to $1,921,463 for the six months ended June
30, 2002. The major components of the $4.5 million selling, general and
administrative expense were as follows: a) various consultants of approximately
$0.9 million; b) salaries of approximately $1.0 million; c) travel expense of
approximately $0.4 million; d) legal expense of approximately $0.3 million; e)
promotional expense of approximately $0.3 million; and f) laboratory expense of
approximately $0.5 million which includes general consumables used in the
Isolagen Process and various supplies used in our clinical trials. The increase
in selling, general and administrative expenses is attributed primarily to: a)
higher salaries due to an increase in the number of employees of the Company; b)
increased travel expenses related to the Company's expansion into the United
Kingdom and Australia; c) higher legal fees related to patent and business
development issues; d) increased consulting fees resulting from the Company's
expansion into new geographic locations; e) increased activity related to the
FDA process; and f) increased marketing and promotion efforts related to the
commencement of operations in the United Kingdom.

INTEREST INCOME. Interest income decreased 44%, or $8,443, to $10,620
for the six months ended June 30, 2003 compared to $19,063 for the six months
ended June 30, 2002. The decrease in interest income resulted from, among other
things, a decrease in the amount of cash on hand by the Company, and a decrease
in interest rates paid on the Company's deposits.

OTHER INCOME. Other income of $55,663 for the six months ended June 30,
2003 represents gains realized on the sale of certain interest bearing
securities denominated in Australian dollars and British pounds held to mitigate
a portion of the foreign currency exposure related to the Company's
international activity. As of June 30, 2003, the Company holds no such
securities.

NET LOSS. Net loss for the six months ended June 30, 2003 was
$4,430,376, as compared to a net loss of $1,827,461 for the six months ended
June 30, 2002. This increase in net loss is attributed primarily to salaries,
travel, consulting, legal, and promotional expenses.

Comparison of the three months ending June 30, 2003 and 2002

REVENUES. Revenues increased $59,425, to $79,425 for the three months
ended June 30, 2003 compared to $20,000 for the three months ended June 30,
2002. The increase in revenues is primarily attributable to the commencement of
operations in the United Kingdom. Included in the three months ended June 30,
2002 was $20,000 in license fees recognized which did not recur in the three
months ended June 30, 2003.

Those revenues which the Company did recognize during the three months
ended June 30, 2003 from its United Kingdom operations were in part reduced by
promotional incentives provided by the Company to doctors utilizing the Isolagen
Process. The Company expects to continue providing such promotional incentives
to doctor's during the introduction phase of the Isolagen Process in the United
Kingdom.

COST OF SALES. Costs of sales increased to $47,867 for the three months
ended June 30, 2003 compared to $0 for the three months ended June 30, 2002. The
increase in cost of sales is primarily related to the commencement of operations
in the United Kingdom.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and
administrative expenses increased 90%, or $1,128,154, to $2,376,023 for the
three months ended June 30, 2003 compared to $1,247,869 for the three months
ended June 30, 2002. The major components of the $2.4 million selling, general
and administrative expense were as follows: a) various consultants of
approximately $0.4 million; b) salaries of approximately $0.5 million; c) travel
expense of approximately $0.2 million; d) legal expense of approximately $0.1
million; e) promotional expense of approximately $0.1 million; and f) laboratory
expense of approximately $0.2 million which includes general consumables used in
the Isolagen Process and various supplies used in our clinical trials. The
increase in selling, general and administrative expenses is attributed primarily
to: a) higher salaries due

14

to an increase in the number of employees of the Company; b) increased travel
expenses related to the Company's expansion into the United Kingdom and
Australia; c) the payment by the Company of certain soft costs associated with
the construction of laboratory facilities in Houston, TX, London, England and
Sydney, Australia; d) higher legal fees related to patent and business
development issues; e) increased consulting fees resulting from the Company's
expansion into new geographic locations; f) increased activity related to the
FDA process; and g) increased marketing and promotion efforts related to the
commencement of operations in the United Kingdom.

INTEREST INCOME. Interest income decreased 78%, or $11,335, to $3,190
for the three months ended June 30, 2003 compared to $14,525 for the three
months ended June 30, 2002. The decrease in interest income may be attributed
to, among other things, a decrease in the amount of cash on hand by the Company,
and a decrease in interest rates paid on the Company's deposits.

OTHER INCOME. Other income of $32,421 for the three months ended June
30, 2002 represents gains realized on the sale of certain interest bearing
securities denominated in Australian dollars and British pounds held to mitigate
a portion of the foreign currency exposure related to the Company's
international activity. As of June 30, 2003, the Company holds no such
securities.

NET LOSS. Net loss for the three months ended June 30, 2003 was
$2,341,275, as compared to a net loss of $1,180,923 for the three months ended
June 30, 2002. This increase in net loss is attributed primarily to salaries,
travel, consulting, legal, and promotional expenses.

LIQUIDITY AND CAPITAL RESOURCES

Operating Activities

Cash used in operating activities during the six months ended June 30,
2003, amounted to $3,951,085, as compared to the $1,636,244 of cash used in
operating activities during the six months ended June 30, 2002. The increase is
attributed primarily to salaries, travel, consulting, legal, and promotional
expenses.

Investing Activities

Cash used by investing activities during the six months ended June 30,
2003, amounted to $1,045,170 as compared to cash used by investing activities of
$86,327 during the six months ended June 30, 2002. This increase in cash used is
due to the purchase of property and equipment for the Houston, Texas, London,
England, and Sydney, Australia laboratories.

Financing Activities

Cash provided by financing activities during the six months ended June
30, 2003, amounted to $4,011,478 consisting of $3,919,078 raised from the
issuance of preferred stock and $92,400 raised from the issuance of common stock
as compared to cash provided by financing activities of $8,778,762 during the
six months ended June 30, 2002 which consisted entirely of proceeds from the
issuance of preferred stock.

Working Capital

As of June 30, 2003, the Company had a cash balance of $3,292,242. As
of August 7, 2003, the Company had a cash balance of approximately $2.2 million.
The Company does not have any credit facilities with which to fund ongoing
working capital needs. The long-term viability of the Company is dependent upon
successful operation of its business and the ability to raise additional debt
and equity within the near future.

Inflation did not have a significant impact on the Company's results
during the six months ended June 30, 2003.

15

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risk as it relates to foreign currency transactions is
described in Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations.

ITEM 4. CONTROLS AND PROCEDURES

In accordance with Rule 13a-15(b) promulgated under the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), the Chief Executive
Officer and Chief Financial Officer of the Company (the "Certifying Officers")
have conducted evaluations of the Company's disclosure controls and procedures.
As defined under Sections 13a-15(e) and 15d-15(e) of the Exchange Act, the term
"disclosure controls and procedures" means controls and other procedures of an
issuer that are designed to ensure that information required to be disclosed by
the issuer in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified
in the Commission's rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information
required to be disclosed by an issuer in the reports that it files or submits
under the Exchange Act is accumulated and communicated to the issuer's
management, including its principal executive officer or officers and principal
financial officer or officers, or persons performing similar functions, as
appropriate to allow timely decisions regarding required disclosure. The
Certifying Officers have reviewed the Company's disclosure controls and
procedures and have concluded that those disclosure controls and procedures were
effective as of the end of the Company's most recent fiscal quarter.

During the Company's most recent fiscal quarter, there were no changes
in the Company's internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, the Company's internal
control over financial reporting.

PART II - OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

In May 2003, the Company sold 155,750 shares of Series B Convertible
Preferred Stock at $28.00 per share for a gross amount of approximately $4.4
million in a private placement to a total of 81 accredited investors pursuant to
the exemption from registration under the Securities Act of 1933 provided by
Rule 506 of Regulation D. The Company complied with the applicable requirements
of Regulation D and filed appropriates Forms D. Each share of Series B
Convertible Preferred Stock is convertible into eight shares of the Company's
common stock, at any time at the option of the holder of such shares. The Series
B Convertible Preferred Stock accrues dividends at 6% per annum payable in cash
or additional shares of Series B Convertible Preferred Stock. Fordham Financial
Management, Inc. acted as the Company's placement agent in connection with the
offer and sale of the Series B Convertible Preferred Stock. After deducting the
aggregate costs and expenses associated with the offer and sale of the shares of
the Series B Convertible Preferred Stock, the Company actually received
approximately $3.9 million. The Company also issued to Fordham Financial
Management, Inc. a warrant to purchase 124,600 shares of the Company's common
stock for a purchase price of $3.50 per share (subject to adjustment from time
to time in accordance with the terms of the warrant).

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The annual meeting of the Company's stockholders was held on June 18,
2003. At that meeting, four proposals were submitted to a vote of the Company's
stockholders: (1) To approve the adoption of the Isolagen, Inc. 2003 Stock
Option and Appreciation Rights Plan; (2) To ratify the appointment of Pannell
Kerr Forster of Texas, P.C. as the Company's auditors for the year ending
December 31, 2003; (3) To amend the Company's Certificate of Incorporation to
provide for the classification of the Board of Directors into three classes of
directors with staggered terms of office; and (4) To elect seven directors to
hold office until his or her successor is duly elected and qualified.

At the close of business on the record date for the meeting (which was
May 1, 2003), there were 15,310,181 shares of Common Stock outstanding and
entitled to be voted at the meeting and 3,038,506 shares of Series A Convertible
Preferred Stock entitled to be voted at the meeting. Each share of Common Stock
is entitled to one vote per share, and each share of Series A Convertible
Preferred Stock is entitled to two votes per share.

16

Holders of 16,225,113 shares of voting stock (representing a like number of
votes) were present at the meeting, either in person or by proxy. The following
table sets forth the results of the voting:

With respect to Proposal 1, 2 & 3, these proposals were duly and
validly approved by the stockholders. With respect to Proposal 4, each nominee
received the favorable votes and each such nominee was duly and validly elected
by the stockholders.

ITEM 6. EXHIBITS AND REPORTS

(a) EXHIBITS

EXHIBIT NO. IDENTIFICATION OF EXHIBIT
----------- -------------------------

31.1 Certification of Chief Executive Officer pursuant to
Rule 13a-14(a) under the Securities Exchange Act of
1934, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

17

31.2 Certification of Chief Financial Officer pursuant to
Rule 13a-14(a) under the Securities Exchange Act of
1934, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

32.1 Certification of Chief Executive Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.

32.2 Certification of Chief Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.

18

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

ISOLAGEN, INC.

Date: August 12, 2003 By: /s/ Jeffrey W. Tomz
--------------------------------------
Jeffrey W. Tomz, CFO and Secretary
(Principal Executive and
Financial Officer)

19

INDEX TO EXHIBITS